New data from trials of Opdivo support its efficacy in recurrent metastatic renal cell carcinoma
The drug has been hailed as new standard of care in mRCC due to promising survival outcome rates and objective response rates, say GlobalData analysts.
Four abstracts presented at this year’s American Society of Clinical Oncology (ASCO) conference on 18 May have strengthened the body of research into Bristol-Myers Squibb’s Opdivo (nivolumab), hailing it as the new standard of care in recurrent metastatic renal cell carcinoma (mRCC), according to analysts with research and consulting firm GlobalData.
As explored in GlobalData’s most recent renal cell carcinoma (RCC) report, Opdivo is set to help the RCC market hit $3.6 billion by 2023, and these recent data further explore the relationship between disease progression and the benefits of Opdivo treatment.
Maxime Bourgognon, PharmD, GlobalData's Analyst covering Oncology and Hematology, states that trials producing such data have done much to demonstrate Opdivo’s positive qualities, such as promising survival outcome rates, objective response rates, and toxicity.
Bourgognon explains: “Trials of Opdivo have measured the drug against Afinitor, a competitor in the mRCC space. For example, several studies have verified the association between response rate and survival in mRCC patients treated with Opdivo (Escudier et al., 2016; Motzer et al., 2016).
“Abstracts from the Motzer et al., analysis revealed that patients are more likely to demonstrate tumour response with Opdivo compared to Afinitor, and tumour response is correlated with patient survival, meaning tumor response is clinically significant. In another study, McDermott et al. have reported promising long-term overall survival of patients treated with Opdivo during the course of the Phase I and II trials, which both preceded the pivotal Phase III Checkmate-025 trial (McDermott et al., 2016).”
Dan Roberts, GlobalData’s Senior Analyst covering Oncology and Hematology, adds: "These long-term results support the initial data published in the New England Journal of Medicine in September 2015, and further demonstrate that Opdivo significantly improves survival with a good quality-of-life.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance